Dual targeting of chemoresistance and ferroptosis in gastric cancer: DDR1/VEGFR2 inhibitor K-13 synergizes with docetaxel from preclinical models to phase Ib/II clinical trial - PubMed
3 hours ago
- #Gastric Cancer
- #Ferroptosis
- #Chemoresistance
- K-13 is a novel DDR1/VEGFR2 inhibitor that shows a synergistic effect with docetaxel in gastric cancer (GC).
- The combination therapy demonstrates significant antitumor activity in various preclinical models including GC cell lines, organoids, and xenograft models.
- Mechanistically, K-13 plus docetaxel inhibits RRM2, blocks the AKT/mTOR pathway, reverses chemoresistance, and induces ferroptosis.
- The strategy is being evaluated in an ongoing phase Ib/II clinical trial, with initial partial responses observed.
- Dual inhibition of DDR1 and VEGFR2 presents a promising approach to overcome docetaxel resistance in GC.